Suchergebnisse - "Cantini, Fabrizio"

PubPharm (14)

1

Immune Therapy, or Antiviral Therapy, or Both for COVID-19 : A Systematic Review

enthalten in: Drugs | 2020

von Cantini, F. | Goletti, D. | Petrone, L. | +3

2

Remission maintenance after tocilizumab dose-tapering and interruption in patients with giant cell arteritis : an open-label, 18-month, prospective, pilot study

enthalten in: Annals of the rheumatic diseases | 2019

von Nannini, C. | Niccoli, L. | Sestini, S. | +3

CommentIn: Ann Rheum Dis. 2021 Nov;80(11):e184. - PMID 31690621

3

Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease : a multicenter retrospective study

enthalten in: Clinical rheumatology | 2016

von Emmi, G. | Talarico, R. | Lopalco, G. | +12

4

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

enthalten in: The New England journal of medicine | 2015

von Mease, P. | McInnes, I. | Kirkham, B. | +110

5

Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab

enthalten in: Rheumatology (Oxford, England) | 2015

von van der Heijde, D. | Breban, M. | Halter, D. | +9

6

Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab : a case report

enthalten in: BMC musculoskeletal disorders | 2015

von Niccoli, L. | Cassarà, E. | Kaloudi, O. | +3

7

Adalimumab, etanercept, infliximab, and the risk of tuberculosis : data from clinical trials, national registries, and postmarketing surveillance

enthalten in: The Journal of rheumatology. Supplement | 2014

von Cantini, F. | Niccoli, L. | Goletti, D.

8

Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors : data from clinical trials and national registries

enthalten in: The Journal of rheumatology. Supplement | 2014

von Cantini, F. | Niccoli, L. | Goletti, D.

9

Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis : an approach to a personalized medicine

enthalten in: Arthritis care & research | 2013

von Gremese, E. | Carletto, A. | Padovan, M. | +14

10

Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry : an appraisal of predictors

enthalten in: The Journal of rheumatology | 2012

von Iannone, F. | Gremese, E. | Atzeni, F. | +29